GHK-Cu vs Thymosin Beta-4
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Also: TB-4, Tβ4
Thymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)
Key Comparison Insights
- GHK-Cu is categorized as Skin & Hair, while Thymosin Beta-4 is Healing.
Detailed Comparison
| Attribute | GHK-Cu | Thymosin Beta-4 |
|---|---|---|
| Category | Skin & Hair | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. | Tbeta4's core action is binding monomeric G-actin, which regulates how cells assemble and disassemble their cytoskeleton and therefore how they migrate. By controlling actin dynamics it promotes cell migration into wounds, encourages new blood vessel growth (angiogenesis), and dampens inflammation. In injured tissue it acts as a chemoattractant, pulling in cells like endothelial cells, keratinocytes, and stem or progenitor cells to rebuild damaged areas. In the heart specifically, research suggests it can reactivate the epicardium, the heart's outer layer, and support survival of cardiac cells under low-oxygen stress. These are well-supported molecular actions, though translating them into proven clinical treatments is a separate question. |
| Common Dosing | 1-2 mg daily (injection) or 0.05% topical Once daily | 2.5-5 mg 2-3x weekly 2-3x weekly |
| Administration | Subcutaneous injection or topical application | Subcutaneous injection, topical for eye conditions |
| Typical Duration | Varies by application | 4-8 weeks typical protocol |
| Best Time to Take | Evening (for skin/recovery) | Morning or split doses |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. | There is genuine peer-reviewed research here, but the human evidence is concentrated in one area: the eye. The ophthalmic formulation RGN-259 (0.1% Tbeta4 eye drops) went through randomized placebo-controlled trials for dry eye and neurotrophic keratopathy, with a phase 2/3 dry eye trial in 317 patients showing significant improvement in corneal staining and ocular discomfort versus vehicle, published in peer-reviewed journals. For the heart, most evidence is preclinical: animal and large-animal studies, including a porcine myocardial infarction model, show Tbeta4 can improve cell engraftment, reduce infarct size, and aid recovery, but a major human cardiac trial program did not deliver an approved drug. Wound healing and hair growth effects are documented mainly in rodents. Across the board, Tbeta4 has a solid molecular story and promising preclinical data, but outside the eye program there are no completed pivotal human trials proving systemic benefit. The widely sold TB-500 research peptide has essentially no controlled human trial data of its own. |
Frequently Asked Questions: GHK-Cu vs Thymosin Beta-4
What is the difference between GHK-Cu and Thymosin Beta-4?
GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. Thymosin Beta-4 is a healing peptide that thymosin beta-4 (tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. its main job is binding and sequestering g-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. it is researched heavily for healing of skin, cornea, and heart tissue, but it is not an fda-approved drug. (the injectable sold as tb-500 is a synthetic fragment marketed as related to tbeta4, not the full natural peptide.) The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Thymosin Beta-4?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Thymosin Beta-4 is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Thymosin Beta-4 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Thymosin Beta-4 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.